Intuitive Surgical, Inc.
) revealed that its da Vinci Fluorescence Imaging Vision System,
well known as Firefly, has received FDA 510(k) clearance for use
in gallbladder surgery.
CYNOSURE INC-A (CYNO): Free Stock Analysis
DELCATH SYS INC (DCTH): Free Stock Analysis
ECHO THERAPEUT (ECTE): Free Stock Analysis
INTUITIVE SURG (ISRG): Free Stock Analysis
To read this article on Zacks.com click here.
The clearance means surgeons would now be able to identify the
biliary duct with the help of the Firefly Imaging system properly
for laparoscopic gallbladder removal surgeries. While performing
surgeries, there is a higher chance of mistakenly identifying the
cystic duct as bile duct leading to injuries due to clipping and
division of the common duct.
However, Firefly Fluorescence Imaging Vision System would help
surgeons use a specialized video camera to view real-time imaging
of bile ducts (cystic duct, common bile duct and common hepatic
Further, it will be able to identify blood flowing in vessels and
tissue during minimally invasive surgical procedures. While using
the Firefly camera, tissue with blood appears green and the same
without blood appears gray.
Intuitive Surgical launched Firefly in 2011 for use with the da
Vinci Si Surgical System in the U.S. and Europe. The system
combines a fluorescent dye with a specialized camera, endoscope
and laser-based illuminator to allow surgeons to identify
vasculature in three dimensions beneath tissue surfaces.
ISRG reported earnings per share of $3.90 in the second quarter
of 2013, missing the Zacks Consensus Estimate of $4.05 per share
but exceeded the year-ago level of $3.75 per share. The company
reported revenues of $579 million for the second quarter, up 8%
year over year and trailed the Zacks Consensus Estimate of $596
Intuitive Surgical significantly lowered its 2013 guidance based
on the company's dismal performance. Due to soft capital sales of
the da Vinci system, the company lowered its revenue expectation
from flat to 7% for 2013. Previously, ISRG had provided its sales
growth guidance in the range of 16% to 19% for 2013. Operating
income is forecast in a band of 37% to 38% of sales (earlier 38%
to 39%) for 2013.
Currently, ISRG retains a Zacks Rank #3 (Hold). Other stocks that
are currently performing well in the medical instruments industry
Delcath Systems, Inc.
Echo Therapeutics, Inc.
). All of them carry a Zacks Rank #2 (Buy).